Veteran healthcare executive and investor with experience across public and private markets, Renee Pilkenton focuses on commercial strategy, corporate development and governance for biopharma and medtech companies. Background blends operating leadership with transaction oversight, board service and capital-raising advisory; frequently engages with PE and VC investors on go-to-market and licensing outcomes.
Veteran healthcare executive and investor with experience across public and private markets, Renee Pilkenton focuses on commercial strategy, corporate development and governance for biopharma and medtech companies. Background blends operating leadership with transaction oversight, board service and capital-raising advisory; frequently engages with PE and VC investors on go-to-market and licensing outcomes.
Combines healthcare operating experience with investor discipline to back commercially-driven biopharma and medtech opportunities. Prioritizes companies with clear go‑to‑market pathways, durable reimbursement or licensing optionality, and measurable commercial milestones. Prefers stage-flexible capital deployment that de-risks through governance, board engagement and pragmatic corporate development—often partnering with PE/VC to bridge technical value into scalable revenue. Time horizon is medium-to-long, with strict milestone-based risk controls and focus on return via commercialization or strategic exit.
Combines healthcare operating experience with investor discipline to back commercially-driven biopharma and medtech opportunities. Prioritizes companies with clear go‑to‑market pathways, durable reimbursement or licensing optionality, and measurable commercial milestones. Prefers stage-flexible capital deployment that de-risks through governance, board engagement and pragmatic corporate development—often partnering with PE/VC to bridge technical value into scalable revenue. Time horizon is medium-to-long, with strict milestone-based risk controls and focus on return via commercialization or strategic exit.
| Trades 1078 | Longs Won 764/1078 70% | Profit Factor 13.51 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $232,719.52 |
| Average Win $66,258.68 | Best Trade (Jul 10) $4.75M | Sharpe Ratio -11.55 |
| Average Loss -$11,931.41 | Worst Trade (Jul 16) -$256,035.28 | Z-Score 8.82 (100%) |
| Commissions $0 | Avg. Trade Length 1y 5m 3w 6d | Expectancy $43,483.46 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 13,514 | 12,162 | 10,811 | 9,459 | 8,108 | 6,757 | 5,405 | 4,054 | 2,703 | 1,351 |